Please login to the form below

Not currently logged in
Email:
Password:

Gwen Fyfe and Norman Selby join Infinity Pharmaceuticals

Will take places of James Tananbaum and Arnold Levine who retire from board of directors

US-based drug discovery and development firm Infinity Pharmaceuticals has appointed Gwen Fyfe and Norman Selby to its board of directors.

Fyfe has over 20 years experience in drug development, including 12 years at Genentech, now part of Roche.

At Genentech she held several senior positions, including VP of its oncology development and VP of the Avastin franchise team. As well as Avastin, Fyfe worked on the development teams of several other major Roche drugs, including Rituxan, Herceptin and Tarceva.

Since she left Genentech in 2009, Fyfe has acted as a consultant for several venture capital firms and biotech companies.

Selby is currently senior adviser at private equity firm Perseus, as well as executive chair of healthcare information company Real Endpoints.

Prior to joining Perseus in 2005, Selby was president and CEO of TransForm Pharmaceuticals, a speciality pharma company focused on innovation in the form and formulation of drug compounds, which was later acquired by Johnson & Johnson.

His other previous roles include executive VP at Citigroup/Citicorp from 1997 to 2000 and several senior positions at McKinsey & Company, where he was a senior partner, including head of the firm's global pharmaceuticals and medical products practice.

Leaving Infinity's board of directors will be James Tananbaum and Arnold Levine, who are both retiring in May. They had been members of Infinity's board of directors since the founding of its predecessor company in 2001.

14th March 2012

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...